loracarbef 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, carbacephem derivatives 1603 76470-66-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • loracarbef
  • lorabid
  • loribid
  • loracarbef hydrate
1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring
  • Molecular weight: 349.77
  • Formula: C16H16ClN3O4
  • CLOGP: -0.47
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 112.73
  • ALOGS: -3.03
  • ROTB: 4
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 94 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 19.07 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 94 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.826 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.564 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.310 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.445 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 74.910 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 50.230 % High 1
herg hERG pIC50 4.643 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.500 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.573 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 69.950 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PRKDC,STK33,SYK,TEK,TGFBR1 24
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,PDK4,PRKDC,STK33,SYK,TEK,TGFBR1,TTK 17
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.400 Moderate 0.66
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.673 High 1
mh-clint Mouse hepatocyte intrinsic clearance 1.807 High 1
mppb Mouse plasma protein binding (% unbound) 77.330 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.637 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 68.180 % High 1
rat-kpuu-brain Rat brain Kpuu 0.007 % Moderate 0.66
rh-clint Rat hepatocyte intrinsic clearance 0.948 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 90.240 % High 1
rppb Rat plasma protein binding (% unbound) 62.020 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 950.605 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1991 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 117.21 109.59 24 3 463585 90164835

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DC08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Second-generation cephalosporins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01DC Second-generation cephalosporins 13 drugs
cefaclorcefamandolecefbuperazonecefmetazolecefminoxcefonicidceforanidecefotetancefotiamcefoxitincefprozilcefuroxime show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Bronchitis indication 32398004 DOID:6132
Pneumonia due to Streptococcus indication 34020007
Lower respiratory tract infection indication 50417007
Upper respiratory infection indication 54150009
Chronic pyelonephritis indication 63302006 DOID:1076
Acute maxillary sinusitis indication 68272006 DOID:2050
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Tonsillitis indication 90176007 DOID:10456
Acute bacterial bronchitis indication 233598009
Pneumonia indication 233604007 DOID:552
Streptococcus pyogenes infection indication 302809008
Infective otitis media indication 312218008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.14 acidic
pKa2 13.72 acidic
pKa3 7.59 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK

External reference:

IDSource
4020247 VUID
N0000148145 NUI
D00916 KEGG_DRUG
121961-22-6 SECONDARY_CAS_RN
4020247 VANDF
C0065295 UMLSCUI
CHEBI:6537 CHEBI
CHEMBL1200610 ChEMBL_ID
DB00447 DRUGBANK_ID
C054920 MESH_SUPPLEMENTAL_RECORD_UI
5284585 PUBCHEM_CID
12247 IUPHAR_LIGAND_ID
3X11EVM5SU UNII
218074 RXNORM
2085 MMSL
4993 MMSL
d00105 MMSL
003667 NDDF
370362008 SNOMEDCT_US
96061006 SNOMEDCT_US

Pharmaceutical products:

None